Screener
Krystal Biotech, Inc. KRYS Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentGross.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands) | March 31,2026 | December 31,2025 |
|---|---|---|
| Leasehold improvements | 27,227 | 27,227 |
| Construction in progress | 12,341 | 8,108 |
| Laboratory equipment | 3,521 | 3,490 |
| Computer equipment and software | 2,616 | 2,559 |
| Furniture and fixtures | 2,191 | 2,152 |
| Total property and equipment | 187,354 | 182,057 |
| Accumulated depreciation | (33,772) | (31,281) |
| Property and equipment, net | $153,582 | $150,776 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s cumulative cost basis?
- Krystal Biotech, Inc. (KRYS) reported cumulative cost basis of $187.35M in Q1 2026.
- How has Krystal Biotech, Inc.'s cumulative cost basis changed year-over-year?
- Krystal Biotech, Inc.'s cumulative cost basis increased by 6.9% year-over-year, from $175.34M to $187.35M.
- What is the long-term trend for Krystal Biotech, Inc.'s cumulative cost basis?
- Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s cumulative cost basis has grown at a 40.5% compound annual growth rate (CAGR), from $33.24M to $182.06M.
Ask your AI about Krystal Biotech, Inc.'s cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude